Contact
20 Mar 20
News
20 Mar 20

Biocomposites Status on Novel Coronavirus (COVID-19)

The recent events and rise of the COVID-19 virus on a global scale have brought challenges to us in ways that were unimaginable at the beginning of the year. We have been following the guidance published by the governments in the countries that we operate in to keep our employees safe, whilst ensuring that we continue to manufacture our lifesaving products.

Our warehouses are stocked – including our newly opened facilities in the US and UK – and we have every confidence that we can continue to meet the needs of our distributors, hospital partners and their surgeons.

We are executing new site access guidelines to restrict visitors to our facilities and conducting a staff capability review across all functions to ensure we have cover in business-critical processes.

As always, we remain focused on supporting the wellbeing and safety of our staff and delivering our excellent products to patients and hospitals worldwide.

Thank you and best wishes through this period.

Contact for Media enquiries

Optimum Strategic Communications

Mary Clark, Stephen Adams, Katie Flint, Nellie Stephens
Tel: +44 (0)20 3922 1906
biocomposites@optimumcomms.com

About Biocomposites

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, South America, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry and sports injuries. Biocomposites’ products are now used in over 1 million procedures per annum and sold in more than 100 countries around the world. In January 2026 Biocomposites was named as one of the UK’s 100 fastest growing technology companies by The Sunday Times. See here for The Sunday Times’ 100 Tech 2026 list. Please visit biocomposites.com to learn more.

About SYNICEMTM bone cements

SYNICEMTM bone cements have been developed to provide the ideal interface between prosthesis and bone – optimised to provide secure and stable fixation for joint replacement surgery, including between irregular bone surfaces and the prosthesis. SYNICEMTM bone cements are manufactured in-house under strictly controlled conditions using out proprietary process. The SYNICEMTM bone cement range includes cements loaded with gentamicin (an antibiotic) for revision procedures in patients at high risk of infection due to gentamicin-sensitive bacteria and patients with compromised immunity. SYNICEMTM bone cements are already used in more than 100 countries around the world.

Other news

Listed below is a list of the 4 most recent news updates made by Biocomposties


Visit our News & Events page

Library

Interested in other types of our content? See a list of some of our most recent below.

Explore Library